Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
Cornely
Oliver A
OA
Department I of Internal Medicine, Infectious Diseases, University of Cologne, Cologne, Germany. oliver.cornely@ctuc.de
Maertens
Johan
J
Bresnik
Mark
M
Ebrahimi
Ramin
R
Dellow
Emma
E
Herbrecht
Raoul
R
Donnelly
J Peter
JP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B